TARGET AUDIENCE
This activity is intended for neuro-oncologists, neurosurgeons and other neuro-oncology specialists involved in the treatment of primary and metastatic central nervous system (CNS) cancers.

OVERVIEW OF ACTIVITY
Brain tumors are a diverse group of neoplasms arising from different cells within the CNS or from systemic tumors that have metastasized to the CNS. Primary brain tumors include a number of histologic types with markedly different tumor growth rates and are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) and glioblastoma multiforme (GBM) based on their histopathologic features. Despite treatment, the median survival for anaplastic oligodendroglioma is 2 to 3 years, and patients with GBM can succumb to their disease within a year of onset. Thus, clinical education regarding standard and evolving best-practice therapeutic management of these neoplasms is essential to improving patient outcomes. To bridge the gap between research and patient care, these proceedings from a case-based CME symposium during the 18^th Annual Meeting of the Society for Neuro-Oncology use the perspectives of leading neuro-oncologists and neurosurgeons to apply evidence-based concepts to routine practice. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES

• Ensure delivery of appropriate treatment for primary brain cancer through the facilitation of a multidisciplinary care plan.
• Apply the results of existing and emerging research to the evidence-based use of chemotherapy and adjuvant chemoradiation therapy for patients with Grade IV GBM.
• Communicate the benefits and risks of bevacizumab, both with and without chemotherapy, to patients with newly diagnosed or recurrent GBM.
• Describe the scientific rationale and recent research results that support ongoing investigation of novel treatments for patients with brain cancer.
• Incorporate key recent clinical trial data into treatment planning for patients with primary CNS lymphomas.
• Recall the design and eligibility criteria for ongoing clinical trials, and consider appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Tracy Batchelor, MD, MPH
Executive Director
Stephen E and Catherine Pappas Center for Neuro-Oncology
Massachusetts General Hospital Cancer Center
Giovanni Armenise-Harvard Professor of Neurology
Harvard Medical School
Neurologist
Massachusetts General Hospital
Boston, Massachusetts

Consulting Agreements: EMD Serono Inc, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Millennium: The Takeda Oncology Company, Pfizer Inc.

Nicholas Butowski, MD
Associate Professor
Department of Neurological Surgery
Division of Neuro-Oncology
University of California, San Francisco
San Francisco, California

Contracted Research: Lilly; Speakers Bureau: Genentech BioOncology, Roche Laboratories Inc.

Howard Colman, MD, PhD
Director of Medical Neuro-Oncology
Associate Professor
Department of Neurosurgery
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Advisory Committee: Novocure, Roche Laboratories Inc; Honoraria: Merck; Royalties: Castle Biosciences Incorporated.

Minesh Mehta, MD
Professor, Radiation Oncology
University of Maryland
Baltimore, Maryland

Board of Directors: Pharmacyclics Inc; Consulting Agreements: Abbott Laboratories, Bristol-Myers Squibb Company, Elekta, Genentech BioOncology, Merck, Novelos Therapeutics Inc, Novocure, Phillips HealthCare Services Ltd; Speakers Bureau: Merck; Stock Ownership: Accuray.

Michael A Vogelbaum, MD, PhD
Professor of Surgery (Neurosurgery)
The Robert W and Kathryn B Lamborn Chair for Neuro-Oncology
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Associate Director
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Cleveland Clinic
Cleveland, Ohio

Consulting Agreement: Merck; Data Safety Monitoring Committee: Neuralstem Inc; Ownership Interest: Infuseon Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Genentech BioOncology and Novocure.

Hardware/Software Requirements:
A high-speed Internet connection

A monitor set to 1280 x 1024 pixels or more

Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

Adobe Flash Player 10.2 plug-in or later

Adobe Acrobat Reader

(Optional) Sound card and speakers for audio

Last review date: February 2014
Expiration date: February 2015